SM
STML

Sabby Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Sabby Management’s Portfolio STML Stock Details STML Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-451
Closed -$415K – 231
2017
Q2 		$415K Buy
451
+79
+21% +$659 0.03% 152
2017
Q1 		$318K Buy
+372
New +$3.39K 0.02% 200

Other funds holding STML

CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LSC
Lyon Street Capital Sausalito, California $67M AUM
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Axa
Axa Paris, France $256M AUM 25.01% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return

Sabby Management's STML Position: Q4 2017 in Review

Sabby Management sold out of Stemline Therapeutics, Inc. (STML) in Q4 2017, closing a stake of 43,749 shares — an estimated $486K sold.

Sabby Management first reported a position in STML in Q4 2013 and held it in 6 quarters. The position peaked at $3.83M in Q4 2016. 80 funds tracked by Wall St. Rank hold STML as of Q4 2017.

  • Sabby Management reported no remaining Stemline Therapeutics, Inc. position as of Q4 2017 after selling out during the quarter.
  • Sabby Management sold 43,749 Stemline Therapeutics, Inc. shares in Q4 2017, an estimated $486K.
  • Sabby Management first reported a position in Stemline Therapeutics, Inc. in Q4 2013 and held it in 6 quarters.
  • Sabby Management's Stemline Therapeutics, Inc. position peaked at $3.83M in Q4 2016.
  • 80 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q4 2017.

Based on Sabby Management's 13F filing for Q4 2017, filed 14 Feb 2018.